# Study to Assess Safety, Reactogenicity and Immunogenicity of the repRNA(QTP104) Vaccine Against SARS-CoV-2(COVID-19)

> **NCT05876364** · PHASE1 · UNKNOWN · sponsor: **Quratis Inc.** · enrollment: 36 (estimated)

## Conditions studied

- COVID-19
- SARS-CoV-2

## Interventions

- **BIOLOGICAL:** QTP104 1ug
- **BIOLOGICAL:** QTP104 5ug
- **BIOLOGICAL:** QTP104 25ug

## Key facts

- **NCT ID:** NCT05876364
- **Lead sponsor:** Quratis Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-11-19
- **Primary completion:** 2022-06-13
- **Final completion:** 2023-08-30
- **Target enrollment:** 36 (ESTIMATED)
- **Last updated:** 2023-05-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05876364

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05876364, "Study to Assess Safety, Reactogenicity and Immunogenicity of the repRNA(QTP104) Vaccine Against SARS-CoV-2(COVID-19)". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05876364. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*